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Abstract
Background: Well-designed and properly executed randomized controlled trials (RCTs) provide the best evidence
on the efficacy of healthcare interventions. Mental health has a strong tradition of using trial to evaluate
treatments, but the translation of research to clinical practice is not always easy. Even well-conducted trials do not
necessarily address the needs of every day care and trials can reflect local needs and the specific culture in which
they are undertaken. Generalizing results to other contexts can become problematic but these trials may,
nevertheless, be very helpful within their own context. Moreover, pathways for drug approval can be different
depending on local regulatory agencies. Local trials are helpful for decision-making in the region from which they
come, but should not be viewed in isolation. National quantity and quality of trials may vary across nations.
The aim of this study is to quantify trialing activity in Italy from 1948 until 2009 and to describe characteristics of
these trials. In addition, we evaluated change over time in three keys aspects: sample size, follow-up duration, and
number of outcomes.
Methods: We used the Cochrane Schizophrenia Group’s register that contains 16,000 citations to 13,000 studies
relating only to people with schizophrenia or schizophrenia-like illness. Randomized controlled trials and controlled
clinical trials undertaken in Italy and involving pharmacological interventions were included.
Results: The original search identified 155 records of potentially eligible studies, 74 of which were excluded
because do not meet inclusion criteria. A total of 81 studies were included in the analysis. The majority of trials
were conducted in north Italy, and published in international journals between 1981 and 1995. The majority of
studies (52 out of 81) used standardized diagnostic criteria for schizophrenia disorder. They were defined as
randomized and used blind methods to administer treatment. However, most failed to report detail regarding
methodological procedures and it is difficult to ascertain which studies are associated with a low risk of bias.
Conclusions: Trials should be designed to address the needs of everyday care with the aim of following large
samples of typical patients in the long term. The Italian tradition in the area of trialing treatments for people with
schizophrenia is not as strong as in many other similar countries and Italy should be producing more, better,
independent, and clinically relevant trials.
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Background
Good mental health research is critical to guide health-
care professionals to make informed decisions about the
effects of most interventions. Early examples do exist of
attempts at fair evaluation of healthcare, including sev-
eral from Italy [1,2]. However, in 1948 the UK MRC
Streptomycin randomized trial was published and
remains a landmark of modern healthcare evaluation
[3]. After that many specialties began to adopt randomi-
zation for the evaluation of treatments.
Mental health has a strong tradition of using trials [4],
but translation of research to clinical practice is not
always easy. For patients, carers, and policymakers, local
data are important. Even well-conducted trials, if under-
taken in a very dissimilar care-culture may be difficult
to apply. Local trials are important and informative
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dies from afar. The totality of evidence must be consid-
ered but the local perspective not ignored. Not to have
local studies leaves all interested in the effects of care
vulnerable to importing data of limited applicability.
Some nations, however, have produced few trials. For
schizophrenia trials, measures of national wealth and
not public health burden loosely predict the research
activity of a country [5]. Italy, however, is the 10th most
wealthy nation in terms of GDP http://www.nationmas-
ter.com/graph/eco_gdp-economy-gdp.
The quality of mental health research, and trials in
particular, may also vary across nations [4]. For example,
the volume and quality of trial research from China has
been considered in many surveys and quality remains a
major concern [6-10]. Elsewhere it has been shown that
pioneering mental health trials from low and middle
income countries are of as mixed quality as their more
accessible counterparts from richer nations but cannot
be identified in commonly used bibliographic databases
[11]. Nearer home, in Europe, Romania’s mental health
research has been the focus of recent investigation and
the increasing dominance of pharmaceutical industry
noted [12].
The Cochrane Schizophrenia Group produces and
maintains a register of all studies http://szg.cochrane.
org/cochrane-schizophrenia-group-specialised-register.
This involves regular and systematic searching of 71
databases. The studies identified in this way are reliably
indexed by country. The aim of this study is to use part
of this dataset to quantify trialing activity in one area of
mental healthcare over time in Italy and describe char-
acteristics of these trials. Specifically, we evaluated con-
tent and risk of bias of Italian trials relevant to people
with schizophrenia from 1948 until 2009 for three key
methodological aspects: sample size, duration, and num-
ber of outcomes.
Methods
Source
We searched the Cochrane Schizophrenia Group Register
without time limitation. The search was made in May
2011 and the last version of register was updated in April
2011. The register includes all published and unpublished
references to randomized, quasi-randomized and con-
trolled clinical trials without language restrictions. The
register is maintained on Meerkat 1.6. The Cochrane
Schizophrenia Group’s register contains 16,000 citations
to 13,000 studies relating only to people with schizophre-
nia or schizophrenia-like illness http://szg.cochrane.org/
cochrane-schizophrenia-group-specialised-register. These
studies are reliably indexed regarding the country of ori-
gin, the interventions under study, and the number of
participants.
Types of studies
We included all randomized controlled trials and con-
trolled clinical trials undertaken in Italy. Studies were
included if any pharmacological treatment was compared
with other active pharmacological treatments or placebo.
Only studies that enrolled patients in Italy were consid-
ered. Multicenter studies were included if all centers
enrolling patients were located in Italy.
Selection of trials and data extraction
From the Cochrane Schizophrenia Group Register we
extracted all records corresponding to studies carried out
in Italy. We examined all titles and abstracts, and
obtained full texts if the word ‘random’ or ‘randomized’
or ‘control’ or ‘controlled’ was present in the title and/or
abstract. MP read the full texts, determined whether they
met inclusion criteria, and extracted the data. Data were
extracted using an electronic spreadsheet. Considerable
care was taken to exclude duplicate publications. In
order to ensure consistency, CB and CEA carried out a
reliability check on all data extracted by comparing the
data abstracted in the electronic spreadsheet with the
paper version of each study. In case of disagreement
between reviewers this was resolved by discussion.
We considered the following variables: year of publica-
tion, geographic area (north, center, south of Italy), lan-
guage of publication (English, Italian), pharmacological
treatment (Antipsychotics according to the WHO Anato-
mical Therapeutic Chemical [ATC] classification system,
other pharmacological treatments), sample size, weeks of
follow-up, diagnostic criteria (standardized criteria such
as DSM or ICD, implicit criteria such as clinical judg-
ment, or unclear criteria), description of random alloca-
tion and blinding (using the Cochrane Collaboration ‘Risk
of BIAS’ tool criteria), number of outcome measures
(number of different psychopathological dimensions ana-
lyzed, as indexed in the specialized register), and use of
the CONSORT flow-diagram.
Data presentation
We calculated simple percentages (%) with 95% confi-
dence intervals (CI). To ascertain whether sample size,
length of follow-up, and number of efficacy measures have
increased in the last 45 years, we used a box plot diagram
and a non-parametric test for trend (extension of the Wil-
coxon rank-sum test). Spearman’s rank correlation coeffi-
cients for all pairs of variables were additionally calculated
using data in continuous format. STATA 11 was used to
carry out the statistical analysis.
Results
General characteristics
The original search identified 155 records of potentially
eligible studies, 74 of which did not meet inclusion
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was retrieved and data extracted. The characteristics of
included studies are presented in Table 1.
Most studies (52% CI 40-63) were conducted in north
Italy, the majority were published between 1981 and
1995 (46% CI 34-57), and 72% (CI 60-81) were in Eng-
lish. The majority of studies evaluated antipsychotic
drugs (79%, CI 69-87), while a minority assessed the
beneficial effect of other drug treatments. Most also
used standardized diagnostic criteria for defining schizo-
phrenia (64% CI 53-75), whereas 32% (CI 22-43) used
implicit criteria and 4% (CI 1-10) do not specify any
diagnostic criteria.
Methodological characteristics
Most trials were of short duration, with only 20 (24.6%
CI 15.7-35.5) being of medium or long-term follow-up
(13 weeks or more) (Table 2). In 10 cases the length of
follow-up was unclear. Duration does not increase over
time (z for trend = -0.41, P = 0.685) (Figure 2). Spear-
man’s rank correlation coefficient confirmed no associa-
tion between year and length of follow-up (rho = -0.030;
P = 0.814)
Two-thirds of trials had less than 40 participants (67%
CI 55-77); sample size only minimally increased over
time (Figure 3), as shown by Spearman’s rank correla-
tion coefficient (rho = 0.259; P = 0.020) but not by test
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Figure 1 PRISMA flow diagram.
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of standardized diagnostic criteria progressively
increased, accounting for more that 70% of trials pub-
lished after 1995 (17/23), the use of implicit criteria
dropped, accounting for less than 20% of trials pub-
lished after 1995 (4/23).
Most trials were described as ‘randomized’ even
though only seven (9% CI 4-17) provided details about
the methods of allocation (Table 2). In 23 studies (28%
CI 19-40) the allocation procedure was unclear. Single
blind was adopted in six studies (7% CI 3-15), double
blind was adopted in 47 studies (58% CI 47-69). For the
remaining 28 studies (35% CI 24-46) it was unclear if
blinding was used or not.
The number of outcomes measures ranged from 1 to
5 in 33 studies (41%, CI 30-52), from 6 to 15 in 35 trials
(43%, CI 32-55) and from 16 to 60 in 13 studies (16%
CI 9-26). Numbers of outcomes measures increases over
time (z for trend = 3.32, P = 0.001) (Figure 4). Spear-
man’s rank correlation coefficient confirmed the associa-
tion between year and number of outcomes (rho =
0.436; P < 0.001).
The CONSORT statement was first published in 1996
[13]. Two of the 23 studies since that time reported a
patient flow diagram (8% CI 1-28).
Discussion
To our knowledge, this is the first survey investigating
content and volume of trial activity in Italy. Although the
majority of Italian schizophrenia trials were published in
international journals, most failed to report basic metho-
dological details such as, for example, information about
the methods of random allocation, and its concealment
from the study investigators, or how blinding was pre-
served. It is therefore difficult to ascertain which studies
are associated with a low risk of bias. This compelling
issue similarly applies to trial activity conducted in other
countries. China, for example, a country which has pro-
gressively increased its production of randomized studies
in the last 10 years, is still under scrutiny for some aspects
of trial quality, including random allocation, blinding, and
dropout reporting. This seems quite relevant in different
areas of medicine [14], as well as in mental health [15].
Poor reporting in mental health is common, involves both
high and low income countries [4], and leads to risk in
interpreting results [16]. In most cases it is not possible to
go beyond identifying studies that seem to be randomized
trials. This further reinforces the need to develop tools to
better describe and appraise the adequacy of the randomi-
zation process in a culturally sensitive manner. Clearly,
random allocation is a scientific process and it should not
differ across cultures, but its reporting should take into
consideration the different meaning that the world ran-
dom might have in different cultures.
Table 1 Characteristics of schizophrenia drug trials
published in Italy from 1948 to 2009 (n = 81 studies)
(n) % (95% CI)
Area of Italy
North 42 51.8 (40.4-63.0)
Center 19 23.4 (14.7-34.1)
South 20 24.6 (15.7-35.5)
Year of publication*
1948-1980 20 25.3 (16.2-36.3)
1981-1995 36 45.5 (34.3-57.1)
1996-2009 23 29.1 (19.4-40.4)
Language of publication
English 58 71.6 (60.4-81.0)
Italian 23 28.4 (18.9-39.5)
Drug treatment
Antipsychotics 64 79.0 (68.5-87.2)
Other drugs 17 20.1 (12.7-31.4)
Diagnostic criteria
Unclear 3 3.7 (0.77-10.4)
Standardized criteria 52 64.2 (52.7-74.5)
Implicit criteria 26 32.1 (22.1-43.3)
*Two unpublished studies not included
CI confidence interval.
Table 2 Main methodological characteristics of
schizophrenia drug trials published in Italy from 1948 to
2009 (n = 81 studies)
n % (95% CI)
Sample size
Min-20 22 27.1 (17.8-38.1)
21-40 32 39.5 (28.8-50.9)
40-max 27 33.3 (23.2-44.6)
Length of follow-up (weeks)
Unclear 10 12.3 (6.08-21.5)
2-4 30 24.6 (15.7-35.5)
5-12 21 25.9 (16.8-36.8)
13+ 20 24.6 (15.7-35.5)
Randomization
Randomized, no details 51 62.9 (51.5-73.4)
Randomized with details 7 8.6 (3.54-16.9)
Unclear 23 28.4 (18.9-39.5)
Blinding
Single blind 6 7.4 (2.76-15.4)
Double blind 47 58.0 (46.5-68.9)
Unclear 28 34.5 (24.3-45.9)
Outcome measures (n)
1-5 33 40.7 (29.9-52.2)
6-15 35 43.2 (32.2-54.6)
16-60 13 16.0 (8.83-25.8)
Patient flow diagram
Yes 2 2.4 (0.30-8.63)
No 79 97.6 (91.3-99.6)
CI confidence interval
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Page 4 of 7The Consolidated Standard of Reporting Trial (CON-
SORT) statement [13,17] facilitates complete and trans-
parent reporting, aids critical appraisal and interpretation
of results. This simple checklist for reporting has been
widely adopted [18]. Good trial reporting is important
not only for guiding clinicians towards correct decision-
making, but also for regulatory agencies working on drug
approval. Certainly, clinicians and regulatory authorities
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Figure 2 Length of Italian schizophrenia drug Trials published between 1984 and 2009 (n =8 1 ) . The horizontal line represents the
median, the box extends to cover the interquartile range and the vertical line extends to the extremes.
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[19]. Researchers and editors no longer have an excuse
for bad reporting.
In Italy, in this subspecialty, while sample size increased
only minimally over time, patient selection criteria and
outcome assessments have become much more sophisti-
cated, as suggested by the increase in use of standardized
diagnostic criteria and by the steadily increase in the num-
ber of outcome measures. Although this trend may have
increased the internal validity of findings, it has neverthe-
less allowed study of only highly refined groups of people
with schizophrenia. This increasing drift from real world
practice makes it difficult to apply trial results to typical
patients [20,21]. Similarly, we observed that the number of
outcome measures has increased during the last 45 years.
This confusion of measuring suggests, at the very least, a
lack of consensus on what is important. Another example,
if one was needed, supporting the need for a set of core
outcome measures in this area [22]. Also increasing num-
bers of measures inevitably enhanced the probability of
detecting chance significant differences. Rarely had the
trials addressed this issue in the statistical analysis or in
the interpretation of findings.
Our survey has some limitations. First, we did not
include international multicenter studies where Italy was
one site, possibly losing studies with good sample sizes
and potentially better reporting. Second, as our focus
was drug trials only, we collected no data on content
and volume of trial activity in other fields of schizophre-
nia treatment, including psychological treatments, psy-
chosocial interventions, and organizational approaches.
This limits the generalizability of our findings, as we do
not know if the current standard of drug trials can be
considered representative of the whole spectrum of trial
activity. Finally, we focused our survey on some indica-
tors only, while it would have been of interest to
describe trial activity with respect to other aspects, such
as for example setting, intention to treat versus per pro-
tocol analysis, dropout reporting, economic support,
ethics committee approval, and consent ‘rituals’.
Conclusions
The Italian tradition in the area of evaluating treatments
for people with schizophrenia is not as strong as in other
similar countries [5]. Perhaps Italy has relied too much
on studies undertaken outside its borders. There is an
opportunity to produce more, better, independent, and
nationally and internationally clinically relevant trials.
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